Markolf Hanefeld
#128,330
Most Influential Person Now
Researcher and physician
Markolf Hanefeld's AcademicInfluence.com Rankings
Markolf Hanefeldphilosophy Degrees
Philosophy
#6119
World Rank
#9093
Historical Rank
Logic
#3308
World Rank
#4444
Historical Rank

Download Badge
Philosophy
Markolf Hanefeld's Degrees
- Doctorate Medicine Harvard University
Why Is Markolf Hanefeld Influential?
(Suggest an Edit or Addition)Markolf Hanefeld's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial (2002) (2389)
- Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial (2006) (1681)
- Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. (2003) (1655)
- Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial (2009) (1317)
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial (2019) (1256)
- Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up (1996) (930)
- Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. (2007) (800)
- Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. (2004) (629)
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus (2006) (628)
- Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. (2000) (556)
- Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. (1999) (400)
- Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). (1995) (400)
- Postprandial glucose regulation and diabetic complications. (2004) (346)
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial (2019) (311)
- Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. (2004) (271)
- Acarbose Slows Progression of Intima-Media Thickness of the Carotid Arteries in Subjects With Impaired Glucose Tolerance (2004) (257)
- One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. (2004) (246)
- In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. (2004) (240)
- The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. (2008) (238)
- Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study. (2003) (235)
- Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial (2010) (231)
- Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. (1999) (230)
- Therapeutic Potentials of Acarbose as First-Line Drug in NIDDM Insufficiently Treated With Diet Alone (1991) (193)
- Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial (2016) (193)
- Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) (2012) (190)
- Diabetes Intervention Study: Multi-Intervention Trial in Newly Diagnosed NIDDM (1991) (185)
- Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study (2005) (179)
- Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes* (2007) (178)
- Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes (2005) (169)
- Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. (2007) (165)
- The STOP-NIDDM Trial: An international study on the efficacy of an α-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data (1998) (163)
- Postprandial glucose regulation: new data and new implications. (2005) (161)
- Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. (2002) (157)
- Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass (2002) (156)
- Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide (2018) (156)
- The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo‐controlled trial (2002) (151)
- Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update. (2006) (150)
- Increased intimal-medial thickness in newly detected type 2 diabetes: risk factors. (1999) (148)
- A long‐term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double‐blind, parallel‐group comparison trial (2005) (144)
- Relationship Between Hypoglycemic Episodes and Ventricular Arrhythmias in Patients With Type 2 Diabetes and Cardiovascular Diseases: Silent Hypoglycemias and Silent Arrhythmias (2014) (141)
- Natural History of Cardiovascular Disease in Patients With Diabetes (2008) (140)
- Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol (2005) (140)
- Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant α-lipoic acid (1995) (137)
- Differential White Blood Cell Count and Type 2 Diabetes: Systematic Review and Meta-Analysis of Cross-Sectional and Prospective Studies (2010) (136)
- Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. (2000) (131)
- Metabolic diseases and their possible link to risk indicators of periodontitis. (2000) (130)
- Post‐challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima‐media thickness: the RIAD Study (2000) (122)
- Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal‐F1) (2014) (119)
- Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial (2016) (117)
- The role of acarbose in the treatment of non-insulin-dependent diabetes mellitus. (1998) (116)
- Evaluation of a Diabetes Management System Based on Practice Guidelines, Integrated Care, and Continuous Quality Management in a Federal State of Germany (2008) (114)
- Das Metabolische Syndrom (2006) (112)
- The Finnish Diabetes Risk Score is associated with insulin resistance and progression towards type 2 diabetes. (2009) (111)
- Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis (2010) (108)
- Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data (2004) (108)
- Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). (2014) (106)
- Is Hyperglycemia a Cardiovascular Risk Factor? (2011) (104)
- In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance. (2002) (103)
- Subclinical inflammation in newly detected Type II diabetes and impaired glucose tolerance. (2002) (99)
- Hypoglycemia and Cardiovascular Risk: Is There a Major Link? (2016) (91)
- In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. (1998) (88)
- Rosiglitazone RECORD study: glucose control outcomes at 18 months (2007) (88)
- Impaired fasting glucose is not a risk factor for atherosclerosis (1999) (86)
- Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes (2007) (83)
- Association of the calpain-10 gene with type 2 diabetes in Europeans: results of pooled and meta-analyses. (2006) (83)
- Association of sulphonylurea treatment with all-cause and cardiovascular mortality: A systematic review and meta-analysis of observational studies (2013) (82)
- Pharmacokinetics and clinical efficacy of pioglitazone. (2001) (81)
- The Postprandial State and the Risk of Atherosclerosis (1997) (80)
- The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. (1998) (79)
- Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. (2006) (79)
- Relationship between fasting plasma glucose, atherosclerosis risk factors and carotid intima media thickness in non-diabetic individuals (1998) (78)
- Control of post-prandial hyperglycemia--an essential part of good diabetes treatment and prevention of cardiovascular complications. (2002) (77)
- Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and composition. (1995) (76)
- High-Sensitivity C-Reactive Protein Predicts Cardiovascular Risk in Diabetic and Nondiabetic Patients: Effects of Insulin-Sensitizing Treatment with Pioglitazone (2010) (76)
- Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus. (2005) (75)
- Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study (2007) (73)
- Cardiac implications of hypoglycaemia in patients with diabetes – a systematic review (2013) (69)
- Effects of p-chlorophenoxyisobutyric acid (CPIB) on the human liver. (1980) (66)
- Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study. (2007) (66)
- Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis. (2004) (65)
- Acarbose: oral antidiabetes drug with additional cardiovascular benefits (2008) (63)
- European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses (1998) (61)
- Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION) (2015) (61)
- Improved metabolic control by Ipomoea batatas (Caiapo) is associated with increased adiponectin and decreased fibrinogen levels in type 2 diabetic subjects (2008) (59)
- Structured health care for subjects with diabetic foot ulcers results in a reduction of major amputation rates (2013) (58)
- An update on preventive and regenerative therapies in diabetes mellitus. (2009) (58)
- The lipid triad in type 2 diabetes - prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes. (2004) (57)
- Risk of and risk factors for hypoglycemia and associated arrhythmias in patients with type 2 diabetes and cardiovascular disease: a cohort study under real-world conditions (2015) (56)
- Comparison of the prevalence of the metabolic syndrome by WHO, AHA/NHLBI, and IDF definitions in a German population with type 2 diabetes: the Diabetes in Germany (DIG) Study. (2007) (55)
- Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study* (2006) (55)
- Identification of the UBP1 Locus as a Critical Blood Pressure Determinant Using a Combination of Mouse and Human Genetics (2009) (55)
- Pioglitazone and sulfonylureas: effectively treating type 2 diabetes (2007) (54)
- Insulin and atherosclerosis: how are they related? (2013) (54)
- The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes (2007) (53)
- Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals (1997) (52)
- The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. (2020) (52)
- Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial (2014) (48)
- Leukocyte count and fibrinogen are associated with carotid and femoral intima-media thickness in a risk population for diabetes. (2002) (48)
- Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin-like growth factor I. (2009) (47)
- Relationship between diurnal blood pressure variation and diurnal blood glucose levels in type 2 diabetic patients. (2007) (46)
- Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of Pioglitazone, Metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study (2011) (45)
- Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events (2013) (45)
- Remission of type 2 diabetes following long‐term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11‐year data from a real‐world registry study (2020) (45)
- Increased clearance of low density lipoprotein precursors in patients with heterozygous familial defective apolipoprotein B-100: a stable isotope approach. (1996) (44)
- Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes (2010) (44)
- Rapid determination of total homocysteine in human plasma by using N(O,S)-ethoxycarbonyl ethyl ester derivatives and gas chromatography-mass spectrometry. (1997) (43)
- Predictors of coronary heart disease and death in NIDDM: The Diabetes Intervention Study experience (1997) (41)
- Impact of concentrations of glycated hemoglobin, alpha-tocopherol, copper, and manganese on oxidation of low-density lipoproteins in patients with type I diabetes, type II diabetes and control subjects. (1996) (41)
- Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes (2013) (40)
- The Role of Alpha-Glucosidase Inhibitors (Acarbose) (2007) (40)
- Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk (2008) (40)
- Glibenclamide, but Not Acarbose, Increases Leptin Concentrations Parallel to Changes in Insulin in Subjects With NIDDM (1997) (40)
- The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes (2013) (39)
- A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. (2007) (38)
- Effect of Acarbose on Vascular Disease in Patients with Abnormal Glucose Tolerance (2008) (37)
- Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study) (2008) (37)
- The Current and Potential Therapeutic Use of Metformin—The Good Old Drug (2021) (37)
- Effect of the Angiotensin II Receptor Antagonist Valsartan on Lipid Profile and Glucose Metabolism in Patients with Hypertension (2001) (35)
- The Metabolic Syndrome and Cancer (2013) (35)
- Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk -- results from the PIOSTAT study. (2007) (35)
- Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome (2011) (34)
- Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics. (2001) (34)
- Safety profile of pioglitazone. (2001) (33)
- Dapagliflozin, an SGLT2 inhibitor, for diabetes (2010) (32)
- Determinants of mortality in patients with type 2 diabetes: a review (2016) (32)
- The metabolic vascular syndrome - guide to an individualized treatment (2016) (32)
- Urinary tract infection in patients with diabetes mellitus. (2012) (32)
- Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies. (1998) (32)
- The "glucose pentagon": assessing glycemic control of patients with diabetes mellitus by a model integrating different parameters from glucose profiles. (2009) (32)
- Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials (2016) (31)
- Insulin Use Early in the Course of Type 2 Diabetes Mellitus: The ORIGIN Trial (2013) (31)
- The role of pioglitazone in modifying the atherogenic lipoprotein profile (2009) (30)
- Efficacy of α‐glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia (1994) (30)
- Differences in Glycemic Variability Between Normoglycemic and Prediabetic Subjects (2014) (29)
- Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients (2003) (29)
- Use of insulin in type 2 diabetes: what we learned from recent clinical trials on the benefits of early insulin initiation. (2014) (29)
- Orally-Administered Chemokine Receptor CCR2 Antagonist CCX140-B in Type 2 Diabetes: A Pilot Double-Blind, Randomized Clinical Trial (2012) (27)
- Long-term effect of octreotide in acromegaly on insulin resistance. (1995) (27)
- Sudomotor Testing of Diabetes Polyneuropathy (2018) (27)
- Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study (2014) (26)
- Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial (2009) (25)
- Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes. (2002) (25)
- Combining pioglitazone with a sulphonylurea or metformin in the management of type 2 diabetes (2000) (24)
- Prevalence and atherosclerosis risk in different types of non-diabetic hyperglycemia. Is mild hyperglycemia an underestimated evil? (2000) (24)
- Postprandial hyperglycaemia: noxious effects on the vessel wall. (2002) (23)
- [Prevalence of newly diagnosed type 2 diabetes, impaired glucose tolerance and abnormal fasting glucose in a high risk population. Data from the RIAD study using new diagnostic criteria for diabetes]. (2008) (23)
- ["Diabetes in Germany"(DIG) study. A prospective 4-year-follow-up study on the quality of treatment for type 2 diabetes in daily practice]. (2009) (22)
- Relationship between HbA1c on target, risk of silent hypoglycemia and glycemic variability in patients with type 2 diabetes mellitus. (2011) (22)
- Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes (2011) (21)
- Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update (2020) (21)
- A review of glucagon‐like peptide‐1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus (2017) (21)
- Conversion of IGT to type 2 diabetes mellitus is associated with incident cases of hypertension: a post-hoc analysis of the STOP-NIDDM trial (2012) (20)
- Relation of free and specifically bound leptin to insulin secretion in patients with impaired glucose tolerance (IGT). (2009) (20)
- Impact of hormone replacement therapy on postprandial lipoproteins and lipoprotein(a) in normolipidemic postmenopausal women (1994) (20)
- Work absenteeism in type 2 diabetes mellitus: results of the prospective Diabetes Intervention Study. (1993) (20)
- Intima-Media-Dicke bei Gesunden ohne Risikofaktorenfür Arteriosklerose (2001) (20)
- Characteristics associated with maintenance of mean A1C<6.5% in people with dysglycemia in the ORIGIN trial (2013) (20)
- Beneficial effects on serum lipids in noninsulin dependent diabetics by acarbose treatment. (1991) (19)
- Efficacy and Safety of 300 μg and 400 μg Cerivastatin Once Daily in Patients with Primary Hypercholesterolemia: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study (1999) (19)
- Self-Monitoring of Blood Glucose (2014) (18)
- Diminished susceptibility to in vitro oxidation of low-density lipoproteins in hypercholesterolemia: key role of alpha-tocopherol content. (1999) (18)
- Effect of acarbose on postmeal mononuclear blood cell response in patients with early type 2 diabetes: the AI(I)DA study. (2009) (18)
- Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes. (2009) (17)
- Metabolic Vascular Syndrome: New Insights into a Multidimensional Network of Risk Factors and Diseases (2016) (17)
- Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study. (2008) (17)
- Should antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without? (2012) (17)
- Relationship between adipocyte hypertrophy and metabolic disturbances. (1979) (16)
- Predictors of response to early basal insulin treatment in patients with type 2 diabetes--the EARLY experience. (2014) (16)
- Impaired glucose tolerance is not associated with lipid intolerance. (2002) (16)
- Meta-analysis of long-term studies to assess the effect of acarbose on cardiovascular risk reduction – scientifically credible: Reply (2004) (16)
- [An unusual picture of insulinoma in type-2 diabetes mellitus and morbid obesity]. (1999) (16)
- Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment (2017) (15)
- Efficacy of alpha-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia. (1994) (15)
- The Diabetes Intervention Study (DIS): a cooperative multi-intervention trial with newly manifested type II diabetics: preliminary results. (1985) (15)
- Serum and Plasma Levels of Vascular Endothelial Growth Factors in Relation to Quality of Glucose Control, Biomarkers of Inflammation, and Diabetic Nephropathy (2016) (15)
- Lixisenatide Treatment for Older Patients with Type 2 Diabetes Mellitus Uncontrolled on Oral Antidiabetics: Meta-Analysis of Five Randomized Controlled Trials (2014) (15)
- Mutations of the human hepatic lipase gene in patients with combined hypertriglyceridemia/hyperalphalipoproteinemia and in patients with familial combined hyperlipidemia (1999) (15)
- Association of physical activity with insulin resistance, subclinical inflammation, coagulation, and fibrinolytic biomarkers among population at high risk for type 2 diabetes (2012) (15)
- Very low calorie diet therapy in obese non-insulin dependent diabetes patients. (1989) (15)
- Changes in insulin resistance and cardiovascular risk induced by PPARgamma activation have no impact on RBP4 plasma concentrations in nondiabetic patients. (2009) (14)
- [Intima-media thickness in healthy probands without risk factors for arteriosclerosis]. (2001) (14)
- [Hypoglycemia and cardiac arrhythmia in patients with diabetes mellitus type 2]. (2014) (14)
- Effect of Insulin Glargine and n-3 FA on Carotid Intima-Media Thickness in PeopleWithDysglycemiaatHighRiskfor Cardiovascular Events The Glucose Reduction and Atherosclerosis Continuing Evaluation Study ( ORIGIN-GRACE ) (2013) (13)
- CLINICAL RATIONALE FOR ROSUVASTATIN, A POTENT NEW HMG‐COA REDUCTASE INHIBITOR (2001) (13)
- Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. (2021) (13)
- [The metabolic syndrome and its epidemiologic dimensions in historical perspective]. (2002) (13)
- The adipocyte volume in human adipose tissue: II. Observations in diabetes mellitus, primary hyperlipoproteinemia and weight reduction. (1978) (13)
- Search for mitochondrial DNA mutation at position 3243 in German patients with a positive family history of maternal diabetes mellitus. (2001) (13)
- Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study. (2009) (13)
- „Diabetes in Germany” (DIG)-Studie (2009) (13)
- Human adipocyte volumes: Maximum size, and correlation to weight index in maturity onset-diabetes (1972) (13)
- Determinants for coronary heart disease in non-insulin-dependent diabetes mellitus: lessons from the diabetes intervention study. (1996) (12)
- Efficacy and Safety of Coadministration of Fenofibrate and Ezetimibe Compared with Each as Monotherapy in Patients with Type IIb Dyslipidemia and Features of the Metabolic Syndrome (2009) (12)
- Serum and Plasma Levels of Vascular Endothelial Growth Factors in Relation to Quality of Glucose Control, Biomarkers of Inflammation, and Diabetic Nephropathy (2016) (12)
- The metabolic syndrome--a postprandial disease? (2006) (12)
- Alpha-glucosidase inhibitors for patients with type 2 diabetes: response to van de Laar et al. (2005) (12)
- [History and definition(s) of metabolic syndrome]. (2007) (12)
- The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL (2017) (11)
- Review of approved pioglitazone combinations for type 2 diabetes (2011) (11)
- The anorexigenic peptide neurotensin relates to insulin sensitivity in obese patients after BPD or RYGB metabolic surgery (2018) (11)
- 35th Annual meeting of the European Association for the Study of Diabetes. Brussels, Belgium, 28 September-2 October, 1999. Abstracts. (1999) (11)
- Effects of high doses of oestrogens and androgens on lipoproteins: observations in the treatment of excessive growth with sexual hormones. (2009) (11)
- Reduced incidence of cardiovascular complications and mortality in hyperlipoproteinemia (HLP) with effective lipid correction. The Dresden HLP study. (1984) (11)
- Ackerbohnenproteindiät bei Hypercholesterolämie (1983) (11)
- Treatment of impaired glucose tolerance with acarbose and its effect on intima-media thickness: a substudy of the STOP-NIDDM trial (study to prevent non-insulin-dependent diabetes mellitus). (2006) (11)
- Intra-individual variability and circadian rhythm of vascular endothelial growth factors in subjects with normal glucose tolerance and type 2 diabetes (2017) (11)
- Stable isotope ratio analysis of amino acids: the use of N(O,S)-ethoxycarbonyl trifluoroethyl ester derivatives and gas chromatography/mass spectrometry. (1997) (11)
- Polymorphisms in perilipin gene (PLIN) are not associated with obesity and weight variation in people with high risk of type 2 diabetes. (2008) (10)
- Lixisenatide is Effective and Well Tolerated in Patients with Type 2 Diabetes Mellitus and Renal Impairment (2014) (10)
- Impaired glucose tolerance (IGT) is not associated with disturbed homocysteine metabolism (2000) (10)
- Prevalence of diabetes-specific autoantibodies in patients at risk for adult onset diabetes mellitus. (2009) (10)
- Recovery of Cholesterol and Triacylglycerol in Very-Fast Ultracentrifugation of Human Lipoproteins in a Large Range of Concentrations (1994) (10)
- Hypoglykämie und Herzrhythmusstörungen bei Patienten mit Diabetes Typ 2 (2014) (10)
- Post-prandial hyperglycaemia and vascular disease. (2000) (10)
- Elevated fasting glucose levels predicts IGT and diabetes also in middle-age subjects. (2007) (9)
- Use of diethylaminoethyl-dextran (DEAE-D) in the treatment of hyperlipoproteinemias and obesity. (1987) (9)
- The adipocyte volume in human adipose tissue: 1. Lipid space, normal and maximum values, and the relation to body weight index. (1978) (9)
- Effects of VLCD in obese NIDDM (non-insulin dependent diabetes) on glucose, insulin and C-peptide dynamics. (1989) (9)
- Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysis (2007) (9)
- Das metabolische Syndrom: „common soil“ für Diabetes und Atherosklerose (2006) (8)
- Basal and stimulated hyperinsulinemia in obesity: relationship to adipose-cell size. (1979) (8)
- Relationship between diurnal glucose levels and HbA1c in type 2 diabetes. (2006) (8)
- Hypoglycemia and Cardiovascular Disease: Lessons from Outcome Studies (2015) (8)
- Pulse pressure is a strong predictor of cardiovascular risk: Data of the risk factors in impaired glucose tolerance for atherosclerosis and diabetes and the Sofia Metabolic Syndrome studies. (2009) (7)
- Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assays--an evaluation with samples from the PIOstat study. (2009) (7)
- Application of interactive multivariate data visualisation to the analysis of patient findings in metabolic research (1999) (7)
- STOP-NIDDM: a new paradigm for diabetes prevention? (2002) (7)
- Very Low Density Lipoprotein Overproduction Is Maximally Expressed in Early Insulin Resistant States (1999) (7)
- [Diagnosis of the metabolic syndrome]. (1996) (7)
- Drug therapy for the prevention of type 2 diabetes – is there a medical rationale? (2011) (7)
- [Diabetes and heart failure: a practically oriented critical appraisal]. (2012) (7)
- Small Dense Low‐Density Lipoprotein (LDL) in Non‐Insulin‐dependent Diabetes Mellitus (NIDDM) Impact of Hypertriglyceridemia (1997) (6)
- Untersuchungen zum Verhalten von Lipiden, weiteren Serumparametern sowie Kreislauffunktionen unter UV-Einwirkung (1994) (6)
- Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol (2017) (6)
- Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers (2021) (6)
- Geschichte und Definition(en) des metabolischen Syndroms (2006) (6)
- Grunddaten der „Diabetes in Deutschland“-Studie (DIG) (2006) (6)
- Effects of a bezafibrate sustained release formulation on plasma lipoproteins in patients with hypercholesterolemia. Importance of timing of tablet intake for efficacy. (1988) (6)
- Fluctuations in glycaemia in clinical diabetes mellitus type 2 are not associated with carotid intima-media thickening (2004) (6)
- Is rosiglitazone associated with increased risk for cardiovascular events? (2007) (6)
- Treatment: Alpha Glucosidase Inhibitors (2019) (6)
- Light-to-moderate alcohol consumption, risk factor profile and early atherosclerosis: the RIAD study. (2001) (6)
- Elimination of lipofundin S during the intravenous fat tolerance test in patients with low, medium, and high fasting triglyceride concentrations. (1985) (6)
- Rosiglitazone Improves Postprandial Glycemia and Markers of Endothelial Function in Patients with Type 2 Diabetes (2002) (6)
- Pathogenetic role of adipose tissue lipase deficit for development of hypertriglyceridaemia. (2009) (5)
- Evaluation of the Potential Clinical and Economic Effects of Bodyweight Stabilisation with Acarbose in Patients with Type 2 Diabetes Mellitus (1998) (5)
- [Physical training in obesity]. (1981) (5)
- [Metabolic syndrome: "common soil" for diabetes and atherosclerosis. Novel approaches to an integrated therapy]. (2006) (5)
- Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein The PIOSTAT (2007) (5)
- Hypertriglyceridaemia in mild hypertension: impact on cardiovascular and hormonal reactivity under different stress tests (1999) (5)
- The challenge of the Metabolic Syndrome. (2007) (5)
- Intima‐Media Thickness and Atherosclerotic Plaques in Familial Defective Apolipoprotein B‐100 and Familial Hypercholesterolemia (2002) (5)
- Predictive value of the index of desirable body weight for total body fat mass as measured by dilution of tritiated water--problems and limitations. (1987) (5)
- Erratum to: Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis (2010) (5)
- The Metabolic Syndrome and Cardiovascular Diseases: An Update of Medical Treatment (2014) (5)
- A new HPLC-based assay for the measurement of fructosamine-3-kinase (FN3K) and FN3K-related protein activity in human erythrocytes (2014) (5)
- Outcome studies in type 2 diabetes (2005) (5)
- Effect of Pioglitazone and Ramipril on Biomarkers of Low-Grade Inflammation and Vascular Function in Nondiabetic Patients with Increased Cardiovascular Risk and an Activated Inflammation: Results from the PIOace Study (2011) (5)
- Primäre Prävention des Typ-2-Diabetes (2002) (5)
- Metabolic Basis of Low High Density Lipoprotein in Subjects with Impaired Glucose Tolerance (1999) (5)
- The Metabolic Syndrome and Cardiovascular Diseases: An Update of MedicalTreatment (2014) (5)
- Effects of Pioglitazone versus Simvastatin on Biomarkers of Inflammation in Patients on High Cardiovascular Risk (2011) (4)
- [Glycemic control and cardiovascular benefit: What do we know today?]. (2010) (4)
- Oral glucose tolerance test: to be or not to be performed? (2002) (4)
- Prädiktoren von Glukosetoleranzstörungen in einer Risikopopulation für Typ-2-Diabetes: die RIAD-Studie (2002) (4)
- Clinical Impact of Titratable Fixed-Ratio Combination of Insulin Glargine/Lixisenatide vs. Each Component Alone in Type 2 Diabetes Inadequately Controlled on Oral Agents: LixiLan-O Trial (NCT02058147) (2016) (4)
- [Field bean protein diet in hypercholesteremia]. (1983) (4)
- Is the newly suggested fasting plasma glucose cut-off point for the diagnosis of diabetes the right one? (1999) (4)
- Herausforderung Diabetestherapie : Effekte der Glitazone jenseits der Blutzuckerkontrolle (2009) (4)
- Hyperinsulinemia in patients with low fractional catabolic rate of triglycerides (1981) (4)
- Efficacy of a combined bezafibrate retard-colestyramine treatment in patients with hypercholesterolemia. (1990) (4)
- Metabolisches Syndrom - : Quo vadis et cui bono? (2006) (4)
- The future of the metabolic syndrome. (2009) (4)
- [Coronary heart disease and insulin concentration in type II diabetic patients--results of a diabetes intervention study]. (1992) (3)
- [Drug treatment of hyperlipoproteinemias]. (1977) (3)
- [Postmenopausal hormone substitution and its effects on the climacteric syndrome, body weight and blood pressure]. (1997) (3)
- More exercise for the hyperlipidaemic patients? (1988) (3)
- [Different effects of fibrates on the lipoprotein profile. Comparison of the effectiveness of gemfibrozil and bezafibrate in various types of hyperlipoproteinemia]. (1992) (3)
- A Practical Guide to the Therapy of Type-II-Diabetes: Pathophysiology, Metabolic Syndrome, Differential Therapy, Late Complications (1995) (3)
- Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026–2035 (2017) (3)
- Definition(en) des metabolischen Syndroms (2008) (3)
- [Hyperglycemia and cardiovascular events]. (2004) (3)
- Influence of diet composition on insulin output, carbohydrate tolerance and lipid values in primary hypertriglyceridemia (HT). (1978) (3)
- Initiation of LDL oxidation by copper ions or AAPH yields different kinetic parameters which are correlated. (1997) (3)
- Insulin resistance and metabolic parameters in type 2 diabetic patients. (2002) (3)
- Normnahe postprandiale Hyperglykämie - eine essenzielle Komponente guter Diabeteskontrolle und Prävention kardiovaskulärer Erkrankungen (2007) (3)
- Dipeptidyl peptidase IV (DP IV)-modulations as treatment of impaired glucose tolerance and niddm (2000) (3)
- Prandial hyperglycemia: is it important to track and treat? (2005) (3)
- Acarbose revisited for efficacy, safety and cardiovascular benefits: a key role for controlling glycemic variability (2012) (3)
- Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for “late-onset” hypogonadism: A case report (2019) (3)
- [Relation of blood pressure to the body weight index and to metabolic parameters]. (1973) (3)
- Frühe oder kurzzeitige Insulintherapie bei Typ-2-Diabetes: Stellenwert und Risiko-Nutzen-Bilanz im Rahmen individualisierter Therapiekonzepte (2019) (3)
- [Predictors of abnormal glucose tolerance in persons at risk of type 2 diabetes: the RIAD study]. (2002) (3)
- [Challenge in diabetes therapy: effects of glitazones beyond blood glucose control]. (2009) (3)
- Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus (2017) (3)
- Th-P16:397 Atorvastatin and LDL profile in NIDDM (ALPIN study) (2006) (2)
- On the determination of the distribution functions of the lipoproteins in human sera. (1972) (2)
- Clinical features and treatment of coronary heart disease in diabetes (2015) (2)
- [Behavior of lipids, other serum parameters and cardiovascular functions in ultraviolet therapy]. (1994) (2)
- Hyperlipidämie und Fibrate unter besonderer Berücksichtigung des Diabetes (2001) (2)
- Treatments for the Metabolic Syndrome (2011) (2)
- Zum Beitrag: S2k-Leitlinie Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Alter (2019) (2)
- Acarbose monotherapy in non-insulin-dependent diabetes mellitus — the German experience (1992) (2)
- Single dose treatment of type 2 diabetics by the DP IV-inhibitor P32/98 (2000) (2)
- Advances in lipoprotein and atherosclerosis research : diagnostics and treatment ; proceedings of the 7th International Dresden Lipid Symposium 1991, held at Dresden, June 9-11, 1991 (1991) (2)
- Frauenärztliche Aspekte des metabolischen Syndroms (2006) (2)
- Aktivierungsanalytische Bestimmung von Mangan, Kupfer und Zink in Leberproben des Menschen (1975) (2)
- EFFECTS OF ALEGLITAZAR ON CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH STAGE 3 CHRONIC KIDNEY DISEASE AND TYPE II DIABETES (2013) (2)
- Fat-cell volume in maturity-onset diabetes. (1971) (2)
- Effect of Oral Antidiabetics and Insulin on Lipids and Coronary Heart Disease in Non‐Insulin‐dependent Diabetes Mellitus (1997) (2)
- Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care 2016;39:1108–1114 (2016) (2)
- Loss of fat, water, and protein during very low calorie diets and complete starvation (1987) (2)
- Blutzucker-Senkung und kardiovaskulärer Vorteil: Was wissen wir heute? –Erwiderung (2011) (2)
- Environmental factors and serum lipoproteins (1990) (2)
- The effect of UV irradiation on lipid levels and other serum parameters and on the circulation (1994) (2)
- Timing of intake of lipid lowering drugs: Is that of importance? (1989) (2)
- Effect of nateglinide and glimepiride in reducing postprandial hyperglycaemia in patients with type 2 diabetes mellitus (2005) (2)
- Postprandial state abnormalities: neglected cardiovascular risk factors in diabetes. Introduction. (2000) (2)
- [Metabolic kinetic studies on the pathogenesis of fatty liver]. (1969) (2)
- Postprandial hyperglycemia is a risk factor for cardiovascular death in newly diagnosed type 2 diabetes: The Diabetes Intervention Study (DIS) (2000) (2)
- Restoring early‐phase insulin secretion – the new goal in type 2 diabetes management (2001) (2)
- Fatty acid composition and action of serum lipoproteins on the PGI2-formation after various oil diets in hyperlipoproteinemia. (1984) (1)
- [Cross-over comparison of fava bean protein and HLP diet in patients with hypercholesterolemia (HC)]. (1987) (1)
- IMPAIRED FIBRINOLYSIS AND EARLY ATHEROSCLEROSIS IN IMPAIRED GLUCOSE TOLERANCE AND NEWLY DETECTED TYPE 2 DIABETES (1999) (1)
- Is the level of steroid hormones in the low density lipoprotein (LDL) particles responsible for the prostaglandin I2 inhibitory potency of LDL? (1988) (1)
- Adipositas, Bluthochdruck, Dyslipidämie und Dysglykämie - Multimodales Management gegen das metabolische Syndrom (2005) (1)
- [Therapy of hypertriglyceridemia from a pathophysiological viewpoint]. (1981) (1)
- Dyslipidaemia and the metabolic syndrome: critical issues in improving CVD risk reduction: (2005) (1)
- [Effect of weight reduction on carbohydrate and fatty-acid metabolism in obese, maturity-onset diabetic patients]. (1975) (1)
- [The metabolic syndrome: where are we going and for what benefits?]. (2006) (1)
- [Significance of fatty tissue hypertrophy for the metabolic risk]. (1977) (1)
- [Statistical studies on the pathogenesis of the fatty liver in diabetics]. (1967) (1)
- RELATIONSHIP OF FREE FATTY ACID CONCENTRATION TO THE TURNOVER RATE OF ENDOGENOUS AND EXOGENOUS TRIGLYCERIDES (1981) (1)
- [Importance of adipose tissue hypertrophy for the pathogenesis of maturity-onset diabetes]. (1975) (1)
- The Metabolic Syndrome and Cardiovascular Disease (2013) (1)
- [Studies on the influence of body weight and form of therapy on the development of fatty liver in maturity-onset diabetes]. (1975) (1)
- Commercially sponsored supplements (1998) (1)
- The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale (2020) (1)
- Physical Activity is Strongly Inversely Related To Post-Challenge Plasma Glucose and Glycemic Spikes in a Risk Population for Type 2 Diabetes (2013) (1)
- Relation of lipoprotein lipase activity in adipose tissue to adipocyte volume and its influence in hypertriglyceridemia pathogenesis. (1977) (1)
- [Intensive basic therapy decreases the need for drug treatment and improves glucose control: an important result of the diabetes intervention study]. (1988) (1)
- Shifting the Disease Management Paradigm From Glucose (2009) (1)
- Therapeutical Effects of Endurance Training in Primary Hyperlipoproteinemia (1983) (1)
- [Screening, prevention and early therapy of type 2 diabetics]. (2004) (1)
- Hypertriglyceridemia--independent risk factor or risk marker? (1989) (1)
- [Cardiologic findings in newly manifested type II diabetics of the diabetes intervention study]. (1986) (1)
- Impaired glucose tolerance, the metabolic syndrome and carotid intima-media thickness: The riad study (1999) (1)
- [Early detection of diabetes in visitors to a health fair according to new definition of diabetes]. (1998) (1)
- [Guidelines for the treatment of hypercholesterolemia]. (1990) (1)
- 2.P.199 Significance of insulin like growth factor 1 for macro- and microangiopathy in non-insulin-dependent diabetes mellitus (1997) (1)
- [Modern medical treatment of type 2 diabetes]. (2014) (1)
- [Coronary heart diseases and associated risk factors in newly manifested type II diabetic patients over the course of 5 years]. (1989) (1)
- Metabolic effects of weight reduction in obese diabetics and nondiabetics. (1976) (1)
- Coronary Risk Factors in Adults: The Influence of Nutrition in Early Life (1977) (1)
- [Hyperlipidemia and fibrates with special reference to diabetes]. (2001) (1)
- [On the problems of the significance of paraproteinemia]. (1967) (1)
- Decreasing Postprandial Plasma Glucose Using an α-Glucosidase Inhibitor in Subjects with IGT for the Prevention of Type 2 Diabetes Mellitus: The STOP-NIDDM Trial (2012) (1)
- [Postprandial hyperglycemia as a risk factor for cardiovascular disease. Therapy improves prognosis]. (2004) (1)
- New aspects of turnover of endogenous and exogenous triglycerides. (1987) (1)
- Cross-over Vergleich von Ackerbohnenprotein- und HLP-Diät bei Patienten mit Hypercholesterolämie (HC) (1987) (1)
- Metabolisches Syndrom und Insulinresistenz (2017) (1)
- PIOcomb-Studie: Die Kombination von Pioglitazon mit Insulin glargine führt zu einer Verbesserung von Biomarkern der Insulinresistenz, β-Zellfunktion und der chronisch systemischen Inflammation (BEVAIR-Konzept) (2011) (1)
- Knochenschmerzen im letzten Drittel der Schwangerschaft (1999) (1)
- Frühe Insulintherapie im Netzwerk individualisierter Therapie des Typ-2-Diabetes (2012) (1)
- HYPERTRIGLYZERIDAMIEN ALS EIGENSTANDIGER RISIKOFAKTOR : KONSEQUENZEN FUR DIE THERAPIE (1992) (1)
- Die Diabetesinterventionsstudie DIS - eine multizentrische Interventionsstudie bei Typ-II-Diabetikern (1994) (1)
- Praxis der Insulintherapie bei Typ 2 Diabetikern im Rahmen der DIG-(Diabetes in Germany) Studie (2006) (1)
- Primär- und Sekundärprävention bei Männern und Frauen mit Typ 2 Diabetes in Deutschland: Die Diabetes in Germany (DIG)-Studie – eine prospektive 4-Jahres-Studie zur Therapiequalität des Metabolischen Syndroms sowie der Hypercholesterolämie (2009) (1)
- Postprandiale Hyperglykämie als Risikofaktor bei Herz-Kreislauf-Erkrankungen (2004) (1)
- Abstract 4433: Comparative Effects of Aliskiren and Irbesartan on Blood Pressure, Renin System Activity, and Biomarkers of Cardiometabolic Risk in Patients with Hypertension and Metabolic Syndrome (2008) (0)
- [Changes in fat and carbohydrate metabolism after administration of cholinomimetic agents in anesthetized rats]. (1970) (0)
- Correction to: Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol (2018) (0)
- [Controlled studies in German language publications]. (2008) (0)
- THERAPY OF HYPERTRIGLYCERIDEMIA (HTG) FROM THE PATHOPHYSIOLOGIC POINT OF VIEW (1981) (0)
- Editor's introduction (2000) (0)
- Case Control Study of Systemic Biomarkers Related to Diabetic Macular Edema in Patients with Type 2 Diabetes (2015) (0)
- [Modern treatment of diabetes mellitus with sulfonylurea compounds]. (1979) (0)
- RATIONALE THERAPIE DES TYP-II-DIABETES (1996) (0)
- [Biopsy and metabolic findings in blood donors having elevated aminotransferases]. (1969) (0)
- [Role of very-low-density lipoproteins in the pathogenesis of primary hypertriglyceridemia]. (1970) (0)
- [Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes]. (2003) (0)
- [Statistical studies on the effect of diabetes type and its treatment on the extent and occurrence of fatty degeneration of the liver in diabetes mellitus]. (1967) (0)
- [Glucose-independent impact of the glitazones on the cardiovascular outcome]. (2005) (0)
- 2.P.236 A gas chromatography/mass spectrometry method for the quantitation of total homocysteine in human plasma (1997) (0)
- Evaluation der Wirksamkeit von retardierter Nikotinsäure im Vergleich zu Placebo auf die postprandiale Hypertriglyzeridämie bei Patienten mit Metabolischem Syndrom (2010) (0)
- [Liver findings in primary hyperlipoproteinemia (HLP)]. (1973) (0)
- Application of interactive multivariate data visualisation to analysis of metabolic parameters in dependence on the stage of glucose tolerance and impaired fasting glucose (2000) (0)
- To: Strey CH, Young J, Collier M, Florkowski CM, Shand BI, Scott RS (2004) The postprandial state does not impair endothelial function in women with Type 2 diabetes irrespective of glycaemic control. Diabetologia 47:1838–1846 (2005) (0)
- Personen mit Prädiabetes haben höhere Triglyzeridwerte als Personen im Stadium der normalen Glukosetoleranz (2006) (0)
- Differential therapy of Type 2 Diabetes based on underlying pathophysiology (2002) (0)
- ALTERATIONS OF INSULIN SECRETION MODIFYING TRIGLYCERIDE TURNOVER (1981) (0)
- [Biopsy and metabolic findings in blood donors with increased transaminases]. (1969) (0)
- [Metabolic syndrome]. (1996) (0)
- PIOcomb Studie: Die Kombination von Pioglitazon mit Insulin Glargine verbessert die Zusammensetzung der Cholesterin Subfraktionen bei Patienten mit Typ 2 Diabetes mellitus (2011) (0)
- 1.P.296 Triglycerides in familial combined hyperlipidemia (FCHL): Heredity and association with atherosclerotic findings (1997) (0)
- 6.3 Efficacy and Safety of Lixisenatide in Elderly T2DM Patients: Subanalysis from the GetGoal Program (916-P) (2013) (0)
- Investigations on the role of low density lipoproteins in the pathogenesis of the essential carbohydrate-induced hypertriglyceridemia (1970) (0)
- [Integrated drug therapy of the metabolic syndrome]. (1996) (0)
- Incidence of coronary heart disease in type-II-diabetes: Impact of quality of metabolic control (1995) (0)
- 1.P.48 Functional implications of the human lipoprotein lipase Asp9Asn variant: Insights from in vivo kinetic studies (1997) (0)
- Efficacy and Safety of Lixisenatide in Elderly Type 2 Diabetes Mellitus Patients: Subanalysis from the GetGoal Program (2013) (0)
- [The new oral antidiabetics. Type 2 diabetes under control only with tablets?]. (2001) (0)
- The importance of oxidative stress in different stages of coronary artery disease (CAD) (1999) (0)
- Impact of obesity on coagulation/fibrinolysis system in Type II diabetics (1994) (0)
- Der Einfluss von Acarbose auf die postprandiale Endothelfunktion bei Typ-2-Diabetes (2008) (0)
- Determination of manganese, copper, and zinc in human liver specimens by activation analysis (1975) (0)
- 2.P.88 Fluvastatin in higher dosage reduces also triglyceride rich lipoproteins (1997) (0)
- 7.5 Oral hypoglycemics (1995) (0)
- Leucocytes count and fibrinogen level are associated with carotid and femoral intima-media thickness (2000) (0)
- Einfluss von Hypoglykämien auf die akute Herzfunktion bei Typ 2 Diabetes-Patienten: Simultane CGM- und EKG- Messungen unter Therapie mit DPP-4 Inhibitoren Vildagliptin und Sitagliptin bei Insulin-behandelten Patienten (2013) (0)
- Das Metabolische Syndrom aus ernährungsmedizinischer Sicht (2003) (0)
- [Methodical studies and directions for the measurement of fatty acid curves in capillary blood]. (1970) (0)
- Fatty acid metabolism and vascular complications in diabetics (1975) (0)
- Dyslipidemia in the Metabolic Syndrome (2005) (0)
- Effects of the angiotensin-II-antagonist valsartan on blood lipids and glucose in hypertensive patients (2000) (0)
- Evaluation der Wertigkeit von RBP4 als Marker des metabolischen Syndroms in einer prospektiven Interventionsstudie mit Pioglitazon (2007) (0)
- [Studies on the relation between hepatic lipid content and reactive hepatitis]. (1972) (0)
- Former-GDR perspective (1992) (0)
- [Rational therapy of Type II diabetes]. (1996) (0)
- Importance of Hypertriglyceridemia as an Independent Risk Factor: Investigations with Familial Combined Hyperlipidemia and Familial Hypertriglyceridemia (1987) (0)
- Effects of Chenodeoxycholic Acid (CD) Treatment on Endogenous Plasma Triglyceride (TG) Transport in Hyperlipoproteinemia (HLP) (1978) (0)
- 1.P.49 Direct effects of the Asn291Ser variant of the human lipoprotein lipase on the catabolism of VLDL1 and VLDL2 in vivo (1997) (0)
- Hypoglycemia is associated with acute changes in the QTc interval and reduced heart rate in type 2 diabetic patients with cardiovascular disease in a real world setting (2017) (0)
- Hintergrund und Design der TECOS-Studie (Trial Evaluating Cardiovasular Outcomes with Sitagliptin) (2011) (0)
- The metabolic syndrome - obesity and hypertension. (2003) (0)
- [Studies on the effect of essential phospholipids in the essential hypertriglyceridemia]. (1969) (0)
- [Presentation of an insulin-treated patient group within the scope of a 5-year study of the Diabetes Intervention Study (DIS)]. (1987) (0)
- [In high risk for diabetes should drugs be used for prevention? (interview by Dr. Judith Neumaier)]. (2002) (0)
- Lipidomic strategies to analyze type 2 diabetes from early insulin resistance to the metabolic syndrome (2009) (0)
- Comparative investigation of basal insulin glargine versus metformin as first line drug in patients with type 2 diabetes on B-Cell and endothelial function (2012) (0)
- Therapie des Diabetes mellitus (2000) (0)
- [Multimodal therapy of dyslipidemia]. (2011) (0)
- Evaluierung der Glukosewerte im Tag/Nacht- Profil bei mit Insulin behandelten Patienten mit Typ 2 Diabetes: Ergebnisse einer explorativen Studie mit kontinuierlichem Glukosemonitoring (CGM) (2010) (0)
- [Physiopathology and clinical aspects of lipid metabolism disorders. Physiopathology of lipid metabolism from the clinical viewpoint]. (1971) (0)
- Erratum (1999) (0)
- PDB18 COST-EFFECTIVENESS OF ACARBOSE IN PATIENTS WITH TYPE-2 DIABETES IN THREE COUNTRIES (2006) (0)
- [The diagnostic value of the D-xylose test]. (1966) (0)
- Pro12Ala Polymorphism of the Peroxisome Proliferator-Activated Receptor-γ2: Association to Type 2 Diabetes and Response to a Glucose Tolerance Test in a Risk Population for Diabetes (2002) (0)
- 8.2 Treatment of dyslipoproteinemia (1995) (0)
- Einfluss der Qualität der Diabeteskontrolle auf systematische Vascular Endothelial Growth Factors (VEGF) und Biomarker der subklinischen Inflammation bei Typ 2 Diabetes (2016) (0)
- Impaired glucose tolerance is not associated with lipidintolerance (2000) (0)
- [Results of protein-sparing modified fasting in hyperlipoproteinemias]. (1985) (0)
- Einfluss einer PPARγ Stimulation auf den postprandialen Glukosemetabolismus und die Proinsulinsekretion der Betazelle bei kardiovaskulären Risikopatienten ohne manifesten Diabetes mellitus (2006) (0)
- Very low density lipoprotein overproduction is maximally expressed in insulin-resistant states (1998) (0)
- Effects of aleglitazar on cardiovascular risk factors in patients with stage 3 chronic kidney disease and type 2 diabetes (2013) (0)
- Low high density lipoprotein (HDL) and impaired glucose tolerance: Insights from stable isotope studies (2000) (0)
- EFFECTS OF THE ANGIOTENSIN-II-ANTAGONIST VALSARTAN ON BLOOD LIPIDS AND GLUCOSE IN HYPERTENSIVE PATIENTS: P2.6 (2000) (0)
- Diabetesfrüherkennung bei Besuchern eines Gesundheitstages nach der neuen Diabetesdefinition (1998) (0)
- Metabolic rates and substrate oxidation in patients with diabetes mellitus type II and hypertriglyceridemia (1994) (0)
- Microalbuminuria is a strong risk factor for atherosclerosis in various degrees of glucose tolerance (2000) (0)
- Regulation der intestinalen Inflammation durch Acarbose (2016) (0)
- [Is primary or secondary prevention of diabetes mellitus in hyperliporoteinemia possible under long-term clofibrate therapy?]. (1976) (0)
- Der Pulsdruck bei Typ-2–Diabetikern mit Herzinfarkt: die DIG Studie (2007) (0)
- [Vascular complications in primary hyperlipoproteinemias (HLP) with special reference to changes in the eye fundus]. (1979) (0)
- [Determination of lipoprotein lipase activity in the epididymal fatty tissue of the rat and its relation to the volume of adipocytes]. (1977) (0)
- Introduction: new approaches to managing diabetic dyslipidaemia. (2005) (0)
- Hypertriglyceridaemia (HTG) as independent risk factor for myocardial infarction in type 2 diabetes: The Diabetes Intervention Study (1993) (0)
- Long-term results of improved dietery compliance in the diabetes intervention study (1995) (0)
- Very fast ultracentrifugation (VFU) of plasma lipoproteins (1994) (0)
- Postprandial hyperglycemia but not fasting blood glucose is a risk factor for cardiovascular death in type 2 diabetes: The diabetes intervention study (DIS) (2000) (0)
- Susceptibility to oxidation of LDL is diminished in postmenopausal women who take estrogens (1994) (0)
- The metabolic syndrome—Common soil for diabetes and cardiovascular disease (2006) (0)
- Relationship between vascular endothelial growth factor (VEGFA), biomarkers of inflammation and dysglycemia (2014) (0)
- [Alcohol and lipid metabolism]. (1981) (0)
- [Statistical investigations into pathogenesis of fatty liver. II. Pathogenic factors of steatosis hepatitis]. (1968) (0)
- Lipidomics in type 2 diabetic patients treated with an intestinal absorption inhibitor versus placebo: implications on metabolic learning and intestinal mucosa transdifferentiation (2008) (0)
- Die Kombination von Pioglitazon mit Insulin ist gut verträglich und vorteilhaft im Vergleich zur Kombination von Insulin mit Metformin. Ergebnisse der PIOcomp-Studie (2010) (0)
- Peroxisome proliferator activated receptor (PPAR) γ2-Pro12Ala-mutation and early atherosclerosis: the RIAD study (2001) (0)
- [Volumes of isolated human fat cells--their distributory, maximum size, and relation to the weight index]. (1971) (0)
- [Therapy of hyperlipoproteinemias]. (1980) (0)
- [Significance of triglycerides for other metabolic parameters in the familial metabolic syndrome]. (2003) (0)
- [Free fatty acids in microsamples of capillary blood: fasting levels, progress curves and daily profiles]. (1972) (0)
- [Statistical studies on the pathogenesis of fatty liver. I. Fatty liver and latent diabetes mellitus]. (1968) (0)
- Microalbuminuria is an independent risk factor for increased intima-media thickness: Data from the riad study (1999) (0)
- Frequency and severity of insulin resistance in type 2 diabetes (2000) (0)
- Protective effect of the pro12Ala variant of the human peroxisome proliferator activated receptor γ2 on obesity, insulin sensitivity and glucose tolerance (2000) (0)
- Correlation between VEGF-A, biomarker of inflammation and dysglycemia (2014) (0)
- Increased cholesterol ester transfer protein (CETP) activity modulates composition and metabolic clearance of HDL in insulin resistant states (1999) (0)
- Relationship between glucagon in a lipid-glucose load and carotid intima-media thickness (2000) (0)
- [Clinical studies on the effect of Regadrin of the VEB Berlin-Chemie in the treatment of essential hyperlipemias]. (1970) (0)
- The metabolic syndrome and cardiovascular disease - an ongoing tsunami. (2013) (0)
- [Determination of total body fat by tritium dilution: method and relation of the results to body-mass-index (BMI)]. (1988) (0)
- [Nutrition in hyperlipoproteinemias from the preventive and therapeutic viewpoint]. (1984) (0)
- Aussagekraft von Lipoproteinbestimmungen für die klinische Beurteilung des Effektes der Bewegungstherapie (1984) (0)
- [Differential type 2 diabetes therapy based on pathophysiological aspects]. (2002) (0)
- [Changes in metabolic parameters, especially in fat metabolism, in chronic alcoholics during clinical alcohol deficiency]. (1972) (0)
- GW24-e3085 The dual PPAR alpha/gamma agonist aleglitazar has a beneficial effect on atherogenic dyslipidemia in patients with type 2 diabetes (2013) (0)
- [On the diagnosis of Waldenström's macroglobulinemia]. (1966) (0)
- Persons with impaired glucose tolerance have higher triglyceride values and insulin resistance than persons with normal glucose tolerance (2007) (0)
- PC-FUNKTIONALITAT MIT SPS-STABILITAT (1998) (0)
- Wirkungen physischer Konditionierung im Rahmen der Kurorttherapie auf den Lipidmetabolismus (1990) (0)
- Abstract-Thema: Pioglitazone und Simvastatin haben komplementäre Effekte auf die subklinische Entzündung bei Patienten mit erhöhtem kardiovaskulären Risiko: Die Piostat-Studie (2006) (0)
- Hepatic oversecretion of small, cholesterol-rich very low density lipoproteins (VLDL2, SF 20–60) in familial combined hyperlipidemia (FCHL) (2000) (0)
- EASD News Section January 2004 (2004) (0)
- [Primary prevention of type 2 diabetes]. (2002) (0)
- STOFFWECHSELERKRANKUNGEN ALS POTENTIELLES PARODONTITISRISIKO (1999) (0)
- Grundriß der Ernährungslehre. 2. Aufl. Herausgegeben von H.‐A. Ketz. 410 Seiten, 117 Tab., 95 Abb. VEB Gustav Fischer Verlag, Jena 1984. Preis: DDR 41,00 M; Ausland 51,00 M (1985) (0)
- Signifikanz des Metabolischen Syndroms als kardiovaskulärer Risikofaktor bei Typ 2 Diabetes: Hat das Metabolische Syndrom ein höheres Risiko als die Einzelkomponenten? Ergebnisse der DIG-Studie (2007) (0)
- Beziehungen zwischen latenten nächtlichen Hypoglykämien, Nüchternglukose und postprandialen Glukoseverläufen nach einem standardisierten Frühstück bei insulinpflichtigen Typ 2 Diabetikern ermittelt mittels kontinuierlichem interstitiellen Glukosemonitoring (2009) (0)
- Moderne medikamentöse Therapie des Typ-2-Diabetes – Hin zur personalisierten Therapie (2015) (0)
- Direkter Angriff auf das kardiovaskulsre Risiko (2005) (0)
- Zum Beitrag: „Testosteronmangel im Alter – was ist zu tun“ (2021) (0)
- Albuminurie und Typ 2-Diabetesrisiko – Eine prospektive Studie (2010) (0)
- Multimodale Lipidtherapie bei Diabetes (2012) (0)
- Hat die Blutdruckamplitude (Pulspressure) Einfluss auf die Proteinurie bei Patienten mit Diabetes mellitus Typ 2 (2006) (0)
- Therapiequalität bei Typ-2-Diabetes in Deutschland: Die DIG-Studie (Diabetes in Deutschland): Basisdaten und 2-Jahres-Untersuchung (2008) (0)
- [Studies on the effect of essential phospholipids in essential hypertriglyceridemia]. (1969) (0)
- Metabolisches Syndrom und seine Komponenten als Risikofaktoren für Diabetes bei Personen mit gestörter Glucosetoleranz: Ergebnisse der STOP-NIDDM Studie (2008) (0)
- Vergleich der Sterblichkeitsraten bei Typ 2 Diabetikern in Deutschland im Rahmen der DIG-Studie zu den Ergebnissen der Studien ACCORD, ADVANCE und VATD (2009) (0)
- KONSEQUENZEN UND PRAXIS DER THERAPIE : FETTSTOFFWECHSELSTORUNGEN IM ALTER (1996) (0)
- Diagnostischer Wert von klinischen Befunden und Biomarkern als mögliche Risikofaktoren für die diabetische Retinopathie: Ergebnisse einer Kohortenstudie mit optischer Kohärenztomografie (OCT) (2019) (0)
- »Dresdner Trunk« - proteinsubstituiertes modifiziertes Fasten (2004) (0)
- Normnahe Blutzuckerkontrolle oder HbA1c < 7 % bei Typ-2-Diabetes – hat 2008 die diabetologische Weltsicht erschüttert oder dringt die Sonne durch den Nebel? (2009) (0)
- [The relation between lipoprotein fractions, sex and IHD in patients with primary hyperlipoproteinemia]. (1982) (0)
- intima-media thickening Fluctuations in glycaemia in clinical diabetes mellitus type 2 are not associated with carotid (2012) (0)
- Vergleich der Parameter der Blutzuckerexkursion nach einer Testmahlzeit bei Typ-2-Diabetikern unter Glargin- vs. Metformin-Monotherapie bei normnahnen HbA1C-Werten (2008) (0)
- Auswirkung von Pioglitazon und Simvastatin auf die Plasmaspiegel von Visfatin und Adiponektin bei Nichtdiabetikern (2006) (0)
- Mittels CGMS ermittelte Determinanten für Hypoglykämien bei Typ 2 Diabetikern mit normnahen HbA1C-Werten (2009) (0)
- Auswirkungen von Depot-Exenatide auf kardiovaskuläre Endpunkte bei Patienten mit Typ-2-Diabetes mellitus: Ergebnisse der EXSCEL-Studie (2018) (0)
- Wirksamkeit und Sicherheit von Albiglutid bei Patienten mit Typ 2 Diabetes und gestörter Nierenfunktion: Ergebnisse der HARMONY 8 Studie (2014) (0)
- [Effect of chlorfibrinic acid on the triglyceride and glycogen contents of human liver as well as on blood-level forming metabolites]. (1972) (0)
- Dyslipidämie ist bereits im normotensiven Bereich mit Störungen der Blutdruckregulation assoziiert (2006) (0)
- Moderne medikamentöse Therapie des Typ-2-Diabetes (2014) (0)
- [Results of linseed oil and olive oil therapy in hyperlipoproteinemia patients]. (1984) (0)
- Effekt der Acarbose-Behandlung im Vergleich zu Placebo auf die Leukozytenzahl vor und nach einer Testmahlzeit: The Effect of Acarbose on sub-clinical Inflammation and Immune-response in early type 2 Diabetes and risk of Atherosclerosis (AI(I)DA) Studie (2007) (0)
- Effizienz und Sicherheit eines neuen Chemokin Rezeptor 2 Antagonist, CCX140-B bei Patienten mit Typ 2 Diabetes (2012) (0)
- The plurimetabolic syndrome and mortality: the diabetes intervention study (1994) (0)
- Comparative investigation of basal insulin glargine versus metformin treatment in drug naive type 2 diabetes patients: results of the GLORY study (2012) (0)
- Koronare Herzkrankheiten (KHK) und das Risiko von KHK bei Patienten mit Typ 2 Diabetes: Die Diabetes in Germany (DIG) Studie (2007) (0)
- Modifikation des Fettverzehrs bei Typ II-Diabetikern: Was kann erreicht werden? (1993) (0)
- Zusammenhang von Parametern der subklinischen Inflammation zur Adipositas in einer normoglykämischen Risikopopulation für Typ 2 Diabetes: Die RIAD Studie (2003) (0)
- Untersuchungen zum Einfluss von Pioglitazon und Simvastatin auf die Leberfunktion bei Hoch-Risiko-Patienten für KHK mit nachgewiesener subklinischer Inflammation (2008) (0)
- Störungen des Lipid- und Lipoproteinstoffwechsels (2000) (0)
- Vergleichende Untersuchungen über die capillarvenöse Blutzuckerdifferenz unter besonderer Berücksichtigung des Hungergefühls (1962) (0)
- Postprandial Glucose New Implications Regulation: New Data and (2005) (0)
- Messung des Bauchumfanges – eine einfache Screeningmethode für Typ 2 Diabetes? (2011) (0)
- Ein einfacher Score zur Früherkennung von Diabetes mellitus Typ2 und Metabolischem Syndrom (2012) (0)
- Multimodale Therapie von Fettstoffwechselstörungen (2011) (0)
- Praxis der Insulintherapie bei Typ 2 Diabetikern in Deutschland: erste Ergebnisse der Diabetes in Germany (DIG) Studie (2006) (0)
- Hyperlipoproteinämien bei Typ II-Diabetikern, Untersuchungen zu Prävalenz, Inzidenz und Behandlungsergebnissen (1992) (0)
- [Problems of long-term treatment of hyperlipoproteinemia with clofibrinic acid]. (1973) (0)
- Metabolische Ursachen einer differenten Energieverwertung bei adipösen Männern und Frauen (1992) (0)
- Postprandialer Status und subklinische Entzündung bei neu entdecktem Typ 2 Diabetes – die AI(I)DA-Studie (Wirkung von Acarbose auf die subklinische Inflammation und Immunantwort bei Typ 2 Diabetes und das Arterioskleroserisiko) (2007) (0)
- Zur Epidemiologie der Hypertonie bei definierten Stoffwechselstörungen (1981) (0)
- Vergleich der Versorgung von geriatrischen Diabetikern in Pflegeheimen mit geriatrischen Diabetikern, die im häuslichen Wohnumfeld leben in einer ländlichen Region Sachsens (2008) (0)
- Insulintherapie bei Diabetes mellitus Typ 2: patientenzentriert, rechtzeitig, nutzen-risiko-bilanziert; Standortbestimmung 2019 nach dem ADA/EASD-Konsensus 2018 (2020) (0)
- Beziehung zwischen HbA1c- Zielwert der ADA und glykämischer Variabilität sowie Auftreten und Dauer latenter Hypoglykämien bei Patienten mit Diabetes mellitus Typ 2 (2009) (0)
- Adiponectin und Leptin: postprandialer Verlauf und die Beziehungen zu den Parametern der Insulin-Glukose-Homöostase in verschiedenen Glukosetoleranzstadien (2003) (0)
- Moderne Fettstoffwechseltherapie bei Patienten mit Diabetes mellitus – Was ist neu? (2013) (0)
- Untersuchung der Glukoseschwankungen von gesunden Probanden, Prädiabetikern und Diabetikern erhoben mittels continuous glucose measurement system (CGMS) (2009) (0)
- Unterzuckerung und Herzerkrankung - eine komplikationsreiche Verbindung (2015) (0)
- Medikamentöse Prävention des Diabetes mellitus Typ 2 – Wenn eine Lebensstiländerung nicht ausreicht ... (2008) (0)
- Beziehungen zwischen Hypoglykämien, Glukoseschwankungen und Arrhythmien bei Patienten mit Diabetes mellitus Typ 2 und kardiovaskulären Erkrankungen (2012) (0)
- Diabetologie und Stoffwechsel (2017) (0)
- Beziehung Zwischen Komponenten Des Metabolischen Syndroms Und CRP Im Kontext Mit Etablierten Risikofaktoren In Einer Hochrisikogruppe Für Koronare Herzkrankheit (2006) (0)
- [Interpretation of oral glucose tolerance tests]. (2009) (0)
- Wechselbeziehungen zwischen Energieverwertung, Na-K-ATPase-System und Fettgewebslipolyse bei Adipositas (1991) (0)
- Das „Glukosepentagon“– ein Modell zur Vereinigung der langfristigen und akuten glykämischen Einstellung (2010) (0)
- Vergleich der Therapiequalität des Typ 2 Diabetes im Rahmen einer Diabetesvereinbarung auf der Grundlage von Praxisleitlinien mit der Qualität der Therapie ohne eine solche Vereinbarung: Die DIG-Studie (Diabetes in Germany) (2007) (0)
- Patienten mit neu entdecktem Diabetes mellitus Typ 2 haben signifikant höhere Triglyzeridwerte als Patienten mit normaler und gestörter Glukosetoleranz (2006) (0)
- Effekte einer Therapie mit Pioglitazon und oder Simvastatin auf verschiedene Parameter des metabolischen Syndroms bei kardiovaskulären Risikopatienten ohne manifesten Diabetes mellitus (2006) (0)
- [Activation analysis of human tissue samples: manganese, copper, and zinc in the liver]. (1973) (0)
- Bedeutung der Triglyzeride für weitere metabolische Parameter bei familiärem metabolischem Syndrom (2003) (0)
- Adiponektin / Leptin-Ratio als Marker der Insulinresistenz (2006) (0)
- Risikofaktoren für kardiovaskuläre Komplikationen und Mortalität in einer bevölkerungsbasierten prospektiven Studie von Patienten mit Typ 2 Diabetes: Die Diabetes In Germany (DIG) Studie (2009) (0)
- Risikofaktoren für Intima-Media-Verdickung: Ist Adiponektin ein unabhängiger Risikofaktor? Die RIAD Studie (2006) (0)
- Screening, Prävention und frühe Therapie des Typ 2 Diabetes: Die Bestimmung des Nüchternblutzuckers reicht nicht aus (2004) (0)
- Untersuchung zur retinalen Gefäßfunktion bei gut eingestellten Typ-2-Diabetikern mittels dynamischer retinaler Gefäßanalyse (2008) (0)
- Beziehung zwischen Metabolischem Syndrom und Gefäßendothel – eine Beobachtung der RIAD-Studie (2006) (0)
- Blutdruck und Nierenfunktion unter einer Therapie mit Insulin Glargine in Kombination mit Pioglitazon und/oder Metformin. Ergebnisse der PIOCOMB-Studie (2011) (0)
- Glukagon determiniert PAI-1 und t-PA – Aktivität bei Männern mit normaler Glukosetoleranz (2006) (0)
- [Significance of fatty liver as an early symptom of diabetes mellitus and hyperlipoproteinemias]. (1974) (0)
- Glukotrias als Basis: So stellen Sie Ihren Typ 2 Diabetiker richtig ein (2003) (0)
- Pioglitazon in Kombination mit Atorvastatin verbessert die endotheliale Funktion und reduziert das kardiovaskuläre Risikoprofil (2008) (0)
- 5.6 Disturbances in the liver and biliary system (1995) (0)
- [Analysis of steatosis-promoting factors in patients with fatty liver of a large blood donors collective]. (1969) (0)
- [Preliminary report on electronic measurement of volume distribution curves of isolated human fatty cells in obesity and their relations to diabetes mellitus]. (1970) (0)
- Preprandial complementary insulin therapy in overweight patients with type 2 diabetes with regular insulin or with rapid acting insulin analogs (2000) (0)
- Die ACCORD-Studie und die Probleme bei der Interpretation der Ergebnisse (2008) (0)
- [The value of hypertension and metabolic factors on the development of coronary heart disease in type II diabetic patients]. (1988) (0)
- [Physiopathology and clinical aspects of lipid metabolism disorders. Clinical aspects and therapy of primary hyperlipoproteinemias]. (1971) (0)
- Impact of concentration of glycosylated hemoglobin on the lagtime of oxidizability of low-density lipoproteins (1995) (0)
- Risk Factors in Insulin Dependent Diabetics (1983) (0)
- [Effect of propranolol and chlorophenoxybutyric acid (CPJB) on the dynamics of free fatty acids and blood sugar]. (1972) (0)
- Arteriosklerose und Diabetes – die Common-soil-Hypothese (2004) (0)
- Hyperinsulinemia in obesity: Importance of adipose tissue cell size (1983) (0)
- Findings from Preventive Type 2 Diabetes Trials (2005) (0)
- 1. Classification and epidemiology (1995) (0)
- RELATIONSHIP BETWEEN SERUM LIPOPROTEIN FRACTIONS, SEX AND ISCHEMIC HEART DISEASES IN HYPERLIPOPROTEINEMIA (1981) (0)
- Hyperlipoproteinaemia in diabetes mellitus II in the diabetes intervention study - 5 year report on prevalence, course and treatment results. (1990) (0)
- Risk factors for early atherosclerosis in a population at risk for diabetes: the riad study (2001) (0)
- Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients Meta-analysis of risk improvement under acarbose (2003) (0)
- Prevalence and rapid diagnostic of the apolipoprotein E Arg136 - > Cys mutation (1995) (0)
- Abnormal lipid tolerance in subjects with impaired glucose tolerance and type 2 diabetes: Relationship to intima-media thickness (1999) (0)
- Einfluss von zwei Kostformen zur Gewichtsreduktion auf den 72-Stunden-Blutzuckerverlauf (CGMS) bei Typ-2-Diabetikern (T2DM) (2008) (0)
- Metabolic transdifferentiation of the intestinal mucosa in early stage type 2 diabetes and metabolic syndrome – the influence of Acarbose (2008) (0)
- The free fatty acids in microsamples of capillary blood: fasting values, course and daily profile. (1972) (0)
- [Clinical studies on a new preparation for the probeless determination of gastric acidity]. (1966) (0)
- [Peculiarities of infusion therapy and parenteral nutrition in hyperlipoproteinemia]. (1980) (0)
- [Bone pain in the last pregnancy trimester]. (1999) (0)
- Dedication to Professor Hans Haller on Occasion of His 65th Birthday (2009) (0)
- Kontrollierte Studien in deutschsprachigen Publikationen (2008) (0)
- [Diagnostic and physiopathologic evidence by micro-lipid determination in liver punctures]. (1970) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Markolf Hanefeld?
Markolf Hanefeld is affiliated with the following schools: